Comparative study of vaginal danazol vs diphereline (a synthetic GnRH agonist) in the control of bleeding during hysteroscopic myomectomy in women with abnormal uterine bleeding: a randomized controlled clinical trial

Sayyah-Melli, Manizheh; Bidadi, Sanam; Taghavi, Simin; Ouladsahebmadarek, Elaheh; Jafari-Shobeiri, Mehri; Ghojazadeh, Morteza; Rahmani, Vahideh

doi:10.1016/j.ejogrb.2015.10.021

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proven in various studies to reduce the symptoms associated with fibroids, but it has not been proven to exert effects on the fibroid size. Androgenic side effects such as weight gain, muscle cramps, hot flashes, mood changes, depression, acne and hirsutism are commonly reported during the use of androgenic steroids [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

Currently Available Treatment Modalities for Uterine Fibroids

Micić,

Macura,

Andjić

et al. 2024

Medicina

View full text Add to dashboard Cite

Uterine fibroids (leiomyomas and myomas) are the most common benign gynecological condition in patients presenting with abnormal uterine bleeding, pelvic masses causing pressure or pain, infertility and obstetric complications. Almost a third of women with fibroids need treatment due to symptoms. Objectives: In this review we present all currently available treatment modalities for uterine fibroids. Methods: An extensive search for the available data regarding surgical, medical and other treatment options for uterine fibroids was conducted. Review: Nowadays, treatment for fibroids is intended to control symptoms while preserving future fertility. The choice of treatment depends on the patient’s age and fertility and the number, size and location of the fibroids. Current management strategies mainly involve surgical interventions (hysterectomy and myomectomy hysteroscopy, laparoscopy or laparotomy). Other surgical and non-surgical minimally invasive techniques include interventions performed under radiologic or ultrasound guidance (uterine artery embolization and occlusion, myolysis, magnetic resonance-guided focused ultrasound surgery, radiofrequency ablation of fibroids and endometrial ablation). Medical treatment options for fibroids are still restricted and available medications (progestogens, combined oral contraceptives andgonadotropin-releasing hormone agonists and antagonists) are generally used for short-term treatment of fibroid-induced bleeding. Recently, it was shown that SPRMs could be administered intermittently long-term with good results on bleeding and fibroid size reduction. Novel medical treatments are still under investigation but with promising results. Conclusions: Treatment of fibroids must be individualized based on the presence and severity of symptoms and the patient’s desire for definitive treatment or fertility preservation.

show abstract

Section: Resultsmentioning

confidence: 99%

Currently Available Treatment Modalities for Uterine Fibroids

Micić,

Macura,

Andjić

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…The success of hysteroscopic surgical procedures is strongly dependent on constant surgical field visibility, so implementing the best strategy to decrease intraoperative blood loss remains a research priority. Injecting a dilute vasopressin solution directly into the submucosal myoma [26,31], intracervical administration of vasopressin [32], gonadotropin-releasing hormone agonist, danazol [2,33], epsilon-aminocaproic acid (EACA), or oxytocin [30] all have different mechanisms of actions, variable effects, costs, and side effects.…”

Section: Discussionmentioning

confidence: 99%

Intrauterine Instillation of Tranexamic Acid in Hysteroscopic Myomectomy: A Double-Blind, Placebo-Controlled, Parallel-Group Randomized Clinical Trial

Rasheedy

Makled

Abou-Gamrah

et al. 2020

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

“…By contrast, other strategies, such as medication (gonadotropin-releasing hormone agonist (GnRH agonist), selective progesterone receptor modulator (SPRM), and others) are frequently used in the preoperative preparation before hysteroscopic tissue removal, including hysteroscopic myomectomy, because of the advantages of increased hemoglobin level and the shrinkage of tumor size, but the majority of articles are limited to discussing the feasibility and safety of these strategies in the assistance of complete hysteroscopic tissue removal, such as the percentage of myomas resected, the duration of surgery, the fluid deficit, and complications [ 95 , 96 , 97 , 98 , 99 ]. There is still a lack of data on the risk of IUA when the patients were treated with medication before hysteroscopic myomectomy, but some reports have shown no significantly gross change in the endometrium during hysteroscopy between the no pretreatment and pretreatment groups [ 42 , 100 ].…”

Section: Primary Prevention Of Intrauterine Adhesion (Iua)mentioning

confidence: 99%

“…A barrier can be achieved by two strategies; one uses agents and the other is physical or mechanical. Agents act as a barrier, can be solid form, liquid form (hydroflotation agents) or gel form, and the components include polyethylene oxide–sodium carboxymethylcellulose gel and crosslinked hyaluronic acid (CHA) gels [ 71 , 81 , 82 , 96 , 97 , 98 , 99 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 120 , 148 , 149 , 154 , 155 , 156 ]. Physical or mechanical barriers include intrauterine suitable balloon catheters, Foley balloon catheters, Malecot catheters, silicone sheets, and intrauterine devices (IUD) [ 73 , 103 , 104 , 105 , 106 , 107 , 108 ].…”

Section: Primary Prevention Of Intrauterine Adhesion (Iua)mentioning

confidence: 99%

Focus on the Primary Prevention of Intrauterine Adhesions: Current Concept and Vision

Lee

Liu

Chen

et al. 2021

IJMS

107

View full text Add to dashboard Cite

Intrauterine adhesion (IUA), and its severe form Asherman syndrome (Asherman’s syndrome), is a mysterious disease, often accompanied with severe clinical problems contributing to a significant impairment of reproductive function, such as menstrual disturbance (amenorrhea), infertility or recurrent pregnancy loss. Among these, its correlated infertility may be one of the most challenging problems. Although there are many etiologies for the development of IUA, uterine instrumentation is the main cause of IUA. Additionally, more complicated intrauterine surgeries can be performed by advanced technology, further increasing the risk of IUA. Strategies attempting to minimize the risk and reducing its severity are urgently needed. The current review will expand the level of our knowledge required to face the troublesome disease of IUA. It is separated into six sections, addressing the introduction of the normal cyclic endometrial repairing process and its abruption causing the formation of IUA; the etiology and prevalence of IUA; the diagnosis of IUA; the classification of IUA; the pathophysiology of IUA; and the primary prevention of IUA, including (1) delicate surgical techniques, such as the use of surgical instruments, energy systems, and pre-hysteroscopic management, (2) barrier methods, such as gels, intrauterine devices, intrauterine balloons, as well as membrane structures containing hyaluronate–carboxymethylcellulose or polyethylene oxide–sodium carboxymethylcellulose as anti-adhesive barrier.

show abstract

Comparative study of vaginal danazol vs diphereline (a synthetic GnRH agonist) in the control of bleeding during hysteroscopic myomectomy in women with abnormal uterine bleeding: a randomized controlled clinical trial

Cited by 5 publications

References 18 publications

Currently Available Treatment Modalities for Uterine Fibroids

Currently Available Treatment Modalities for Uterine Fibroids

Intrauterine Instillation of Tranexamic Acid in Hysteroscopic Myomectomy: A Double-Blind, Placebo-Controlled, Parallel-Group Randomized Clinical Trial

Focus on the Primary Prevention of Intrauterine Adhesions: Current Concept and Vision

Contact Info

Product

Resources

About